Skip to main content
Clinical Trials/NCT05009186
NCT05009186UnknownNot Applicable

Changing of PSA With Covid-19

Saglik Bilimleri Universitesi1 site in 1 country100 target enrollmentStarted: April 1, 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
100
Locations
1
Primary Endpoint
PSA value

Study Overview

Brief Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19. In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Detailed Description

Patients with positive PCR test results were included in the study. The age of the patient and urea, leukocyte, hemoglobin, platelet, urea, and creatinine values of the patients were recorded. Urinalysis and urine culture were taken from all patients. Acute phase reactants such as sedimentation, C-reaktif protein (CRP), ferritin, and fibrinogen were measured both at the time the patients applied and three weeks after the patient recovered. PSA and free PSA were also measured in the same way. Patients whose symptoms improved and the PCR test result was negative were considered as recovered.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
45 Years to 70 Years (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male patients (>45 and <70 years of age) positive PCR test results were included in the study

Exclusion Criteria

  • •The patients <45 and >70 years of age who described lower urinary tract symptoms who had urinary tract infection who a history of prostate biopsy and previous high level of PSA who history of prostatitis were excluded.

Arms & Interventions

Covid-19 group

Other

We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test

Intervention: PSA value (Other)

Outcomes

Primary Outcomes

PSA value

Time Frame: 2 months

prostate specific antigen

Secondary Outcomes

  • Ferritin, CRP(2 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Omer Gokhan Doluoglu

Ankara Training and Research Hospital

Saglik Bilimleri Universitesi

Study Sites (1)

Loading locations...

Similar Trials